<DOC>
	<DOC>NCT00484536</DOC>
	<brief_summary>The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis</brief_summary>
	<brief_title>Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>relapsing form of MS screening EDSS score 0 5.5, inclusive at least one clinical relapse in the 12 months before screening active disease, defined by set of MRI activity criteria failed prior treatment with betainterferons or glatiramer acetate signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or Hepatitis C or tuberculosis known allergy to gadoliniumDTPA, and/or ingredients of the study drug formulation pretreatment with immunosuppressive or immunomodulatory drugs prior to screening within certain time frames</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>CDP323</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Oral Compound</keyword>
	<keyword>MS</keyword>
</DOC>